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ABSTRACT 
Persistence in the Use of Statins and the Associated Outcomes among 
Chinese Patients with High Risk for Coronary Heart Disease 
Background: Coronary heart disease (CHD) is one of the major causes of death 
in Hong Kong. HMG-CoA reductase inhibitors (statins) showed dose-dependent 
effects on lowering the serum level of low-density lipoprotein cholesterol (LDL-
C). Poor patient adherence to statins can lead to sub-optimal LDL-C control and 
occurrence of CHD events. 
Objectives: To examine the accuracy of patient report and pill count for 
measuring adherence to statin therapy, describe the trend of adherence, identify 
predictors for adherence, and examine the association of variable patient 
adherence with statins to the control of serum LDL-C and healthcare utilization 
in Chinese patients at high risk for CHD. 
Method: A 6-month prospective cohort study was conducted at three outpatient 
clinics of a public teaching hospital in Hong Kong. Patients with CHD or CHD 
risk equivalents and who had been initiated on statin monotherapy for <12 
months were recruited from January to June 2003. Patients' demographic 
information and clinical characteristics were collected at the entry of study. The 
statin prescription was dispensed to the study patients in a bottle with the 
Medication Event Monitoring System (MEMS®). Adherence to dose-count and 
dose-time were recorded by the electronic monitoring device. A face-to-face 
interview was conducted during follow-up visits at month 3 and month 6 to 
assess patient adherence over the previous week, and the number of tablets left in 
the bottle was also counted. Fasting lipid profiles were obtained at baseline and 
the two follow-up visits. Clinical outcomes assessed were percent LDL-C 
reduction and achievement of NCEP ATP III target; economic outcome was 
assessed in terms of total direct medical cost per member per month (PMPM). 
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Results: A total of 102 patients were recruited and 83 of them completed the 
study. Pill count was weakly correlated with MEMS dose-count (rs=0.37, 
p<0.001), while patient report was sensitive to both dose-count and dose-time 
measurements (p=0.022 and p<0.001 correspondingly) using MEMS as a 
validation standard. MEMS dose-time adherence was mildly correlated with 
dose-count (rs=0.43, pO.OOl). The median MEMS adherence to dose-count and 
to dose-time were 95% percentile = 87%-99%) and 78% (25出-75th 
percentile = 17%-92%), respectively. Both dose-count and dose-time adherence 
declined slightly over the first six months of therapy. Living with family 
(RR=0.786, 95%CI=0.6630-0.9315) and duration of therapy (RR=0.988, 
95%CI=0.9774-0.9999) were negative predictors while number of family 
members among those living with family (RR=1.045, 95%CI=L0090-1.0811) 
was a positive predictor for dose-count adherence. Monthly household income 
(RR=1.010, 95%CI=1.0020-1.0171) and history of angina (RR=1.288, 
95%CI=1.0502-1.5809) were positive predictors while living with family 
(RR=0.736, 95%CI=0.5477-0.9900) was a negative predictor for dose-time 
adherence. Sixty-three patients (76%) had achieved target LDL-C per ATP III. 
LDL-C reduction was weakly associated to dose-count and dose-time adherence 
(R2=0.13，pO.OOl and R^=0.048, p=0.047 respectively). A 30% reduction in 
serum LDL-C was correlated to 60% dose-count adherence level. Patient 
adherence to statins was not significantly associated with healthcare utilization. 
Conclusion: Patient report was sensitive to changes of both dose-count and 
dose-time adherence to statin therapy measured by the electronic monitoring 
device while the correlation of pill count adherence to MEMS dose-count was 
low. Adherence to statins was high in a cohort of Chinese patients at high risk for 
CHD and it normalized over time. Number of family members and the presence 
of CHD risk indicators appeared to be influential to patient adherence. A weak 
association between dose-count adherence and LDL-C reduction was found, and 
a marginal association between dose-time adherence and LDL-C reduction were 
observed. Patient adherence to statins was not significantly associated with 
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Chapter 1 Introduction 
1.1 Coronary Heart Disease 
1.1.1 Epidemiology 
Coronary heart disease (CHD) is one of the major causes of death over the 
world. In the United States, more than 1 million Americans suffer a CHD event 
each year, and over 50% are fatal. (Website: National Institute of Health) 
According to World Health Report 2003，cardiovascular diseases (CVD) caused 
up to 16.7 million (29.2%) of global deaths. In China or India alone, the number 
of CVD-related deaths attributed to 77% of the burden, which was greater than 
the sum of all other industrialized countries. (Website: World Health 
Organization) The incidence of CHD in the developing world is rapidly 
increasing as a consequence of aging. Heart attacks and strokes cause death in 
about 12 million people every year. By 2020, 46.4% of all deaths are expected to 
be attributable to CVD and the WHO expects that CHD will be a greater burden 
to the national healthcare systems of the world than any other single disease. 
(Website: World Health Organization) 
Likewise, heart disease is the second most common cause of death in Hong 
Kong and CHD accounts for 68% of deaths from heart diseases. (Chan et al 1999, 
Fu 2001) In the year 2002，heart diseases claimed nearly 5,000 lives (15% of 
2 
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total death). Stroke is the third most common cause of death and is also a major 
cause of disability in Hong Kong. It accounted for over 3,200 deaths in 2002 
(9.4% of total death). (Website: Department of Health, Hong Kong) 
1.2 Hypercholesterolemia and CHD 
Dyslipidemia can be classified as pure hypercholesterolemia, pure 
hypertriglyceridemia and combined hyperlipidemia (with both 
hypercholesterolemia and hypertriglyceridemia). It is estimated that over 
one-forth of the Western populations is hypercholesterolemic. (Nieto et al 1995) 
The causes may be familial, polygenic, post-menopausal or disease-induced. The 
lipid levels in Asians are lower than Caucasians although the Asian lifestyle is 
much Westernized nowadays. (Woo et al 1998, Zhou et al 2003) 
Hypercholesterolemia is strongly associated with heart diseases. Studies have 
demonstrated that elevation in total cholesterol is an independent and significant 
risk factor for CHD. Among all types of lipid components, namely high-density 
lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), 
very low-density lipoprotein cholesterol (VLDL-C) and triglyceride, LDL-C is 
the most predictive factor for CHD. Reducing serum cholesterol level has been 
3 
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shown to lower the incidence of CHD event, and it has been proposed that every 
1% reduction in total cholesterol lowers coronary artery disease by 2%. (Lipid 
Research Clinics Program 1984) In the recently published British Hypertension 
Society (BHS IV) guidelines, serum LDL-C reduction by 30% is considered 
beneficial irrespective of baseline levels. (Williams et al 2004) 
1.2.1 Atherosclerotic plaque and lipoprotein 
It is believed that atherosclerotic process is initiated by cellular injury to the 
vascular endothelium, followed by accumulation of cholesterol and oxidation of 
LDL-C. Rupture of atherosclerotic plaques is likely due to the low collagen 
content but rich leukocytic infiltrates. The plaques might narrow the arteries, 
completely block the arteries, or cause thrombotic clots to form and block the 
arteries. It is therefore important to prevent unstable plaque disruption that 
releases highly thrombogenic factors, which in turn occludes the vessel. 
(Steinberg et al 1989, Davies et al 1991, Ross and Agius 1992) Since lipid 
accumulation is one of the key issues of plaque formation, lipid-lowering 
intervention is critical to prevent CHD events. (Brown et al 1993) 
4 
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1.2.2 NCEPATP III guidelines 
The Expert Panel on Detection, Evaluation and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment Panel, ATP) of the National Cholesterol 
Education Program (NCEP) published management guidelines on the treatment 
of hypercholesterolemia based on population and clinical evidence, and the latest 
guidelines of ATP III was published in 2001. (Anonymous 2001) It provided 
recommendations on CHD risk assessment, target lipid control, therapeutic 
lifestyle changes and pharmacological interventions for hypercholesterolemia. 
1.2.2.1 CHD risk assessment 
The ATP III recommended that initial CHD risk assessment should be 
performed with lipid screening every five years in patients over 20 years of age. 
Further evaluation of CHD risk factors should be considered when serum LDL-C 
is above the optimal level. (Table 1-1) 
5 
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Table 1-1. Optimal level of LDL-C 
Classification of levels LDL-C^ in mg/dL (mmol/L) 
Optimal < 100 (2.6) 
Near or above optimal 100-129 (2.6-3.4) 
Borderline high 130-159 (3.4-4.1) 
High 160-189 (4.1-4.9) 
Very high >190 (4.9) 
a: LDL-C = Low-density lipoprotein cholesterol 
Risk factors that further define the goal of LDL-C are shown in table 1-2. 
(Anonymous 2001，Website: National Institute of Health) 
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Table 1-2. CHD risk factors that affect LDL-C target levels 
Non-modifiable risk factors Modifiable risk factors 
Male gender Low HDL-C^ 
• < 40 mg/dL; 
Ase 
> 60 mg/dL (removes 1 risk 
• Male over 45 years old; factor from total count) 
• Female over 55 years old ” . i … 丁 � b 
High LDL-C 
Family history Physical inactivity 
• Father or brother being Obesity 
diagnosed with CHDC before 
® Diabetes mellitus 
age 55; 
. M o t h e r or sister being Tobacco smoking 
diagnosed with CHD'^  before 
age 65 Uncontrolled hypertension 
a: HDL-C = High-density lipoprotein cholesterol 
b: LDL-C = Low-density lipoprotein cholesterol 
c: CHD = Coronary heart disease 
For patients with multiple CHD risk factors, estimation of their 10-year risk 
for CHD is recommended in order to identify patients required intensive 
treatment for LDL-C control. The Framingham Risk Scoring System includes 
age, gender, smoking status, serum total cholesterol (TC), HDL-C, treatment of 
7 
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hypertension and systolic blood pressure (SBP) to assess the 10-year CHD risk. 
(Appendix A1-A2) ATP III classified risk levels into three categories: (1) patients 
with CHD or CHD risk equivalent are at the highest risk o f �2 0 % over 10 years; 
(2) patients with multiple risk factors and 10-year risk of < 20%; (3) patients 
with 0 to 1 risk factor and have a 10-year risk < 10%. 
1.2.2.2 Target lipid control 
According to the level of risk for CHD, ATP III recommended three target 
levels of LDL-C. (Table 1-3) 
Table 1-3. LDL-C targets for different CHD risk categories 
Risk category LDL-C* goal in mg/dL (mmol/L) 
CHDb or CHD risk equivalents < 100 (2.6) 
(10-year risk > 20%) 
Multiple risk factors (> 2) < 130 (3.4) 
(10-year risk < 20%) 
0-1 risk factor <160(4.1) 
a: LDL-C = Low-density lipoprotein cholesterol 
b: CHD = Coronary heart disease 
8 
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In the ATP III, diabetes mellitus is considered as CHD risk equivalent 
because it can cause damages to coronary arteries and confers a high risk of a 
new CHD event within 10 years. Diabetes is also associated with a higher death 
rate after myocardial infarction. Besides diabetes, existing cerebrovascular 
disease or other forms of clinical atherosclerosis disease such as peripheral 
vascular disease, abdominal aortic aneurysm and carotid artery disease are also 
considered as CHD risk equivalent. (Anonymous 2001, Website: National 
Institute of Health) It is therefore recommended that the lowest LDL-C target 
(less than 100 mg/dL or 2.6 mmol/L) for these patients. 
1.2.2.3 Therapeutic lifestyle changes 
Therapeutic lifestyle changes should be initiated for all patients with 
hypercholesterolemia. ATP III allows total fat to be 25-35% of total calories but 
recommends reduced intake of saturated fatty acids to < 7% of total calories and 
cholesterol to < 200 mg/day. Increased intake of unsaturated fat can reduce 
triglyceride levels and raise HDL-C levels in patients with metabolic syndrome. 
(Anonymous 2001, McKenney 2003) Lower sodium intake, smoking cessation 
and adequate physical activities are also encouraged. Diet enriched with 
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phytosterols significantly reduced LDL-C. (Clifton et al 2003) Regular 
consumption of soy isoflavones may lower cholesterol levels in Japanese and 
Chinese. (Chisato et al 1997，Ho et al 2000) 
1.2.2.4 Pharmacological interventions 
Drug therapy should be initiated immediately in patients with high risk for 
CHD and lipid levels should be evaluated every six weeks until controlled. 
Response and adjustment of therapy can then be monitored every four to six 
months. (Anonymous 2001) The updated NCEP report advised that the intensity 
of lipid-lowering therapy for high risk patients should be sufficient to achieve at 
least 30% reduction in LDL-C. (Grundy et al 2004) 
Lipid-lowering drugs include bile acid sequestrants (cholestyramine, 
colestipol and colesevelam), niacin (nicotinic acid and niaspan), fibrates 
(clofibrate, gemfibrozil and fenofibrate), ezetimibe and 
3-Hydroxy-3-Methyl-Glutaryl Coenzyme A (HMG-CoA) reductase inhibitors. 
Being highly potent and well tolerated by most patients, HMG-CoA reductase 
inhibitors (statins) are generally considered as the drug of choice for the 
treatment of hypercholesterolemia. Statins inhibit the rate-determining step of 
10 
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cholesterol synthesis and promote the catabolism of LDL-C by up-regulating the 
number of receptors on cell surface. Lipid-lowering effect of statin therapy is 
dose-dependent. (Chong et al 2001) Doubling the statin dose is suggested to give 
an additional 5% reduction in total cholesterol and 7% in LDL-C. (Roberts 1997) 
Pregnant women and patients with hepatic impairment should not use statins. 
Statins, except atorvastatin, are usually administrated at night to yield better 
lipid-lowering effect because of higher nocturnal cholesterol synthesis. 
(Kreisberg and Oberman 2003, Thompson 2003) 
The long-term effects of statin therapy were demonstrated in a number of 
large-scale clinical trials. (Table 1-4) The goal of primary prevention with 
LDL-C lowering therapy is to prevent CHD events in CHD-naive patients 
whereas secondary prevention is to prevent recurrence of CHD events. 
Table 1-4. Summary of outcomes of statin therapy 
Study Reduction in Reduction in 
Placebo-controlled trial Intervention N duration events (%) deaths (%) 
Primary prevention 
WOSCOPS" Pravastatin 6595 5 26 32 
40 mg years 
AFCAPS/TexCAPSb Lovastatin 6605 5.2 40 33 
20-40 mg years 
11 
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Secondary prevention 
4S' Simvastatin 4444 5.4 30 42 
20-40 mg years 
CARfid Pravastatin 4159 5 25 19 
40 mg years 
LIPID' Pravastatin 9014 6.1 28 23 
40 mg years 
MIRACl/ Atorvastatin 3086 16 16 --
80 mg weeks 
aiWOSCOPS = The West of Scotland Coronary Prevention Study 
(Shepherd etal 1995) 
b: AFCAPS/TexCAPS = Air Force/Texas Coronary Atherosclerosis Prevention 
Study (Downs et al 1998) 
c: 4S = Scandinavian Simvastatin Survival Study (1994) 
d: CARE = Cholesterol And Recurrent Events Trial (Sacks et al 1996) 
e: LIPID = Long-term Intervention with Pravastatin in Ischaemic Disease Trial 
(1998) 
f： MIRACL = Myocardial Ischaemia Reduction with Aggressive Cholesterol 
Lowering Study (Kinlay et al 2003) 
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1.2.2.5 Adherence to lipid-lowering therapy 
Adherence to lipid-lowering therapy is recognized as an important issue to 
attain the desired CHD risk reduction. ATP III recommends the use of 
multi-disciplinary methods to achieve full effectiveness of the guidelines for the 
prevention of CHD events. Interventions focusing on improving patient 
adherence include simplifying medication regimens, providing explicit 
instruction and counseling, encouraging the use of aids such as diaries and 
pill-boxes, maintaining contact with patients to reinforce adherence, encouraging 
family support, increasing the frequency of visits for monitoring treatment goal, 
increasing the convenience and access to care, and involving patients in their 
care through self-monitoring. Physicians and the health delivery system should 
also implement and support the treatment plan and specialist clinics. 
(Anonymous 2001) 
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1.3 Adherence to drug therapy 
1.3.1 Definition of adherence 
Variable patient adherence to drug treatment began to gain recognition as an 
important factor in drug research in the early 1960s and there is a rising concern 
on the subject ever since. (Cramer 1962, Wood et al 1964) From 1960 to 2004, 
numerous studies were published on the issues of "adherence" or "compliance". 
Relevant terms discussed include adherence, compliance, concordance and 
persistence. Yet, definitions of adherence often vary from study to study. 
Compliance, is defined as one's willingness to follow or consent to the 
wishes of another person. (Haynes 1979) Adherence is the action of sticking to 
or supporting a person or an idea. (Buchmann 1997) It is the extent to which a 
patient's behaviour is consistent with the health care recommendations from the 
patient's perspective. (Haynes 1979, Framer 1999) Adherence to any intervention 
is largely determined by the individual's perception of the risks, benefits and 
costs of the intervention. (Love et al 1991) Concordance, as stated by the Royal 
Pharmaceutical Society of Great Britain, implies patient as the decision maker 
for a practical and ethical goal of treatment. (Vermeire et al 2001) Persistence 
describes whether the patient continuously consumes the medication or not. It 
14 
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measures the duration of time over which a patient continued to receive care and 
illustrates the long-term treatment for chronic diseases. (Applegate 2002) 
From the development of related terms, an increase in the emphasis of 
patient's role and participation is observed that patient-oriented practice is highly 
promoted in recent years. Some investigators use the terms interchangeably. 
(Buchmann 1997) "Adherence" has become the more common and preferred 
term used by today's practitioners, (Farmer 1999) while "persistence" is used to 
describe the long-term pattern of "adherence" over time. (Huss et al 1997) 
Poor adherence may involve such behavior as delay in seeking care, 
breaking of appointment, failure to follow physician's instruction or to fill 
prescriptions, missing doses, self-adjustment of dose or time of administration, 
and self-termination of treatment. (Insull 1997, Vermeire et al 2001) The most 
critical types of patient adherence affecting the success of a drug treatment are 
the dose-count and dose-time adherence to the drug therapy. Therefore, most 
medication adherence studies examined these two types of adherence. 
15 
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1.3.2 Methods to assess adherence 
There are a number of advantages and disadvantages of the currently used 
assessment methods. In previous studies, various methods had been used for 
measuring patient adherence but were not always validated. (Nichol et al 1999) 
Direct measurement of drug levels in urine, blood or plasma provide proof 
that the drug has been taken by the patient. However it is limited to systematic 
drugs, and it can be biased by "white coat effect" that patients take the prescribed 
medication appropriately shortly before a clinic visit. 
Indirect assessment of adherence include counting unconsumed pills, 
reviewing prescription records, patient report, changes in clinical parameters 
(such as blood pressure, cholesterol levels etc.), and using electronic monitoring 
devices. (Roter and Hall 1998) Pill count is frequently used for measuring 
adherence, but there are limitations such as patients failing to return unconsumed 
drugs or discarding them before clinic visit. (Pullar et al 1989) Moreover, the 
counting of liquid dosage by volume can be quite inaccurate. 
It was suggested that reviewing dispensing records might be a reliable 
method to assess adherence in a patient group. (Steiner and Prochazka 1997) 
Pharmacy and insurance records can be used to assess adherence, expressed as 
16 
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proportion of days covered (PDC) with medication supply, in large populations 
over extended periods of time. (Choo et al 1999，Momingstar et al 2002) Using 
dispensing records for adherence assessment can disclose premature 
discontinuation and it can also avoid "Hawthrone effect" or "reactivity" that 
adherence is enhanced because patients are aware of being evaluated. (Rand 
1998, Choo et al 1999, Turner and Hecht 2001) The validity of prescription refill 
records depends on the completeness of the pharmacy database. However, refill 
adherence may overestimate drug consumption because it is assumed that the 
medications are all administered when refill is obtained. 
Patient's self-report is the least costly way to assess adherence and can be 
used in all clinical settings. (Bame et al 1993，Brown and Fitzpatrick 1988， 
Curtin et al 1999) It is suggested to be a valid and reliable method as long as 
questions are asked in a non-threatening, open-ended approach. (Vlaminck 2001) 
However, it has been found to underestimate the prevalence of poor adherence as 
patients are reluctant to admit non-adherent to their prescriptions. (Bumey et al 
1996) This method depends heavily on patient collaboration and is subjected to 
inaccuracy from misinformation provided by the patients. (Rand 1993) 
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Clinical parameters and physiologic responses are related to the effect of 
medication, such as reduction in blood pressure, blood glucose, blood cholesterol 
levels, cell counts or body weight. (Choo et al 1999) Therefore, changes in 
clinical assessment may reflect the underlying patient adherence towards the 
regimen. However, some patients may not be able to achieve target clinical 
indicators despite that they are highly adherent to the treatment. 
Among all, the electronic monitoring device is widely used as a reliable 
method and primary backbone for measuring adherence in many studies since it 
provides continuous data on patient's habit and behaviour. (Choo et al 1999， 
Wagner and Rabkin 2000) The medication event monitoring system (MEMS, 
AARDEX® Ltd.，Zug，Switzerland) contains a microchip processor that records 
the date and time when the prescription vial cap is opened and closed 
successively, for administration of tablet, eye drop，inhalation device, or even 
ointment. (Kass et al 1986, Apter et al 2001, DiMatteo et al 2002, Balkrishnan et 
al 2003) Nonetheless, patient may accidentally or purposefully actuate the 
medication container without taking the medication. 
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In Hong Kong, majority of the residents receive medical care provided by a 
government-funded public health organization (Hospital Authority). Medications 
prescribed from outpatient clinics of public hospitals cost patients HKD 10 per 
item for a 4-month supply since 1 April 2003 and the dispensing records very 
often show 100% adherence. Dispensing record of the outpatient pharmacy is 
therefore unlikely to reflect the degree of partial adherence. Patient report and 
pill count are the two most commonly used methods to monitor patient 
adherence in the local settings. However, both methods were shown to have 
limitations as described above. Over- or under-estimation of patient adherence by 
patient report or pill count can lead to unintended under- or over-dosage, and 
consequently incur unnecessary sub-optimal therapeutic outcomes. The accuracy 
of patient report and pill count methods conducted during routine clinical 
practice therefore need to be examined and validated. 
MEMS is frequently used in clinical trials to assess patient adherence, 
although the high acquisition cost of the electronic device limited its usage in 
routine practice. (Cramer et al 1989) Despite that there are some limitations such 
as improper use of the device, the electronic monitoring method is considered to 
be an objective and reliable method, (Choo et al 1999, Framer 1999, Urquhart 
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1999, Wagner and Rabkin 2000) and it has been used for measuring adherence in 
many different fields such as acquired immunodeficiency syndrome (AIDS), 
(Kastrissos et al 1998, Paterson et al 2000, Safren et al 2003, Berg et al 2004, 
Hinkin et al 2004) asthma, (Apter et al 2001) diabetes, (Rosen et al 2003) 
hypertension, (Straka et al 1996, Urquhart 1999, Bumier et al 2003) juvenile 
rheumatoid arthritis, (Rapoff et al 1998, Rapoff et al 2002) psychiatric disorders 
(Oswald et al 1999, Peveler et al 1999, Diaz et al 2001) and even for topical 
medication. (Balkrishnan et al 2003) 
1.3.2.1 Expressions of adherence measurements 
The degree of patient adherence can be expressed as a continuous variable, 
ranging from 0% to 100%. (Kolbe 2002) It can also be classified dichotomously, 
as "adherent" and "non-adherent" by means of a cut-off value. Some 
investigators have defined an arbitrary cut-off for optimal adherence at 80%. 
(Haynes et al 1976, Psaty et al 1990) This level has not been validated in all 
circumstances and may well vary depending on several factors, such as the 
degree of systemic absorption and half-life of the prescribed substance. (Leenen 
et al 1996, Mallion et al 1996) Many studies have adopted cut-off points at both 
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20% and 80%, where 0 to 19% is non-adherent, 20% to 79 % is partial adherent 
and 80% to 100% is adherent. (Rudd 1994，Insull 1997，Applegate 2002, Benner 
et al 2002) 
1.3.3 Time effect on adherence 
Patient adherence and persistence show decreasing trends with the duration 
of therapy and the greatest decline occurs in the first 6 months. Mean PDC with 
statins was 79% in the first 3 months and 56% in the third to sixth months. 
(Benner et al 2002) In Sweden, pill count adherence on pravastatin was above 
90%, with a gradual decrease over two years. (Eriksson et al 1998) In 
North-American populations, persistence on statin therapy at one year since 
initiation diverges from 33% (Catalan and LeLorier 2000) to 64.3% (Avorn et al 
1998). By the fifth year of statin therapy, merely 13% (Catalan and LeLorier 
2000) to 26% (Benner et al 2002) patients were adherent to the treatment. 
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1.3.4 Predictors of adherence 
Identifying the possible predictors of patient adherence would be useful 
for designing adherence-enhancing interventions. Several factors are shown to be 
predictive for poor patient adherence, such as age, race, education level, 
household income, family support, cigarette smoking, patients' belief, 
co-morbidities, number of concurrent medications and side effects of drug. 
Previous studies revealed that patients who aged 60 years or older were better 
adherents, whereas those under 45 or over 75 years old showed significantly 
lower adherence rates. (Kiortsis et al 2000，Larsen et al 2002, Benner et al 2002) 
The number of household members was found to modify the way Chinese 
elderly family member responded to their health declines. (Kaneda 2003) 
Moreover, the number of close family members was significantly associated with 
the amount of household care received by the elderly members. (Chou and Chi 
2001) Higher levels of adherence were reported among the Caucasians 
comparing to the African-origin groups (Benner et al 2002, Golin et al 2002) but 
few had reported the drug-taking behavior among Asians or Chinese. (Leung et 
al 2001, Molassiotis et al 2002, Fong et al 2003) Overall, higher education and 
household income, cohesive family, positive attitude towards healthy living and 
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patient-healthcare provider relationship may be correlated with increased 
adherence levels. (Roter and Hall 1989，Insull 1997，Avorn et al 1998，Brown 
and Fitzpatrick 1998，Benner et al 2002, Golin et al 2002，Ammassari et al 2002) 
On the other hand, heavy smoking, complex regimens and the presence of 
intolerable side effects may stop patients from adhering to the treatment. 
(Kiortsis et al 2000, Ammassari et al 2002) 
1.3.5 Impact of poor adherence to statins 
An estimated 5-11% of all hospitalizations are linked to poor patient 
adherence, annually representing 1.9 million admissions and costs of USD 25 
billion in the United States. (Sullivan et al 1990，Col et al 1990) Moreover, 
disease complications resulting from non-adherence account for USD 100 billion 
in annual healthcare and productivity losses. (Sullivan et al 1990, Donovan and 
Blake 1992, Berg et al 1993) Prescribing statins to patients did not guarantee 
adequate control of serum lipids. Discrepancy between high clinical efficacy in 
clinical trials and the sub-optimal outcomes observed in clinical practice put 
forward the idea of patient non-adherence to the treatment. Adherence to therapy 
is a primary determinant of treatment success and is significantly related to 
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outcomes for chronic illnesses. (DiMatteo et al 2002) In developed countries, 
adherence to drug therapy averages 50%, and it is lower in less developed 
settings. Poor adherence attenuates optimum clinical benefits and therefore 
reduces the overall effectiveness of drug therapy. 
Forgiving medications such as analgesics can be taken at the patients' will 
without compromising the effectiveness of therapy. Nevertheless, statin is a less 
forgiving drug because the lipid-lowering effect of statin therapy is highly 
dose-dependent. Studies showed that adherence to statin therapy of >80% was 
significantly associated with a lower risk of recurrent myocardial infarction, 
(Wei and Wang 2002) and >75% level of adherence to pravastatin was required 
to demonstrate substantial CHD risk reductions in the Western populations. 
(Anonymous 1997) 
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1.4 Objectives and hypotheses 
The objectives of the present study were，in a cohort of Chinese patients at 
high risk for CHD, to: 
1. Compare the accuracy of patient report and pill count with an electronic 
monitoring device for measuring patient adherence to statin therapy 
Hypothesis: Both methods over-estimate patient adherence 
2. Describe the trend of patient adherence to statin therapy over time and 
identify predictors of adherence to statins 
Hypothesis: Adherence to statin therapy declines over time 
3. Examine the association between variable patient adherence to statin therapy 
and the control of serum LDL-C 
Hypothesis: Higher adherence is associated with higher serum LDL-C 
reduction 
4. Examine the association between variable patient adherence to statins and the 
utilization of healthcare resources 
Hypothesis: Patient adherence is inversely associated with direct 
medical costs measured from the perspective of the local 
public healthcare organization 
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Chapter 2 Materials and Methods 
2.1 Study site 
The protocol of the prospective cohort study was approved by the Clinical 
Research Ethics Committee of The Chinese University of Hong Kong in 
December 2003. This study was conducted in three outpatient clinics of the Li 
Ka Shing Specialist Clinics at the Prince of Wales Hospital. The Prince of Wales 
Hospital is under the management of Hospital Authority (a public health 
organization) and is one of the largest teaching hospitals in Hong Kong. 
Providing 1，400 beds and a wide scope of specialist clinics, the Prince of Wales 
Hospital serves for the majority of residents in the New Territories East Cluster. 
In the year 2001-02, the Prince of Wales Hospital contributed to 624,386 (12%) 
of the total 5,432,486 specialist outpatient attendances in the public sector. 
(Website: Census and Statistics Department, Hong Kong) Majority of the 
lipid-lowering agents are prescribed from the Cardiology Clinic, Diabetes Clinic 
and Lipid Clinic. Atorvastatin and simvastatin are the most commonly prescribed 
statins. The three clinics are operated weekly, serving approximately 420 patients 
per week (250 at the Cardiology Clinic, 150 at the Diabetes Clinic and 20 at the 
Lipid Clinic). Routine follow-up appointments are usually arranged every three 
to six months upon physicians' discretion and clinic vacancies. Waiting time of 
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new referral case ranges from a few months to one year. Refill medications will 
not be prescribed if a patient breaks the appointment, and the patient needs to 
provide another referral letter if he or she fails to attend two clinic visits. 
2.2 Patient selection criteria 
2.2.1 Inclusion criteria 
Male and female Chinese patients aged 18 years and above were invited to 
participate if all of the followings were satisfied: 
> attending one of the three study clinics; 
> receiving either atorvastatin or simvastatin for less than 12 months; 
> had a history of CHD or CHD risk equivalent factor; 
> had documented baseline lipid profile within one month prior to statin 
initiation; and 
> was able to provide written informed consent. 
CHD risk equivalents include diabetes mellitus, a 10-year risk for 
developing CHD > 20% determined by Framingham risk scoring system 
(Appendix A1-A2)，or other clinical forms of atherosclerotic disease including 
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peripheral arterial disease, abdominal aortic aneurysm and symptomatic carotid 
artery disease. (Anonymous 2001) 
2.2.2 Exclusion criteria 
Patients were excluded from the present study if any one of the following 
circumstances was met: 
> receiving other non-statin lipid-lowering agents; 
> enrolled in another clinical study or the compliance checking clinic; 
> scheduled for elective surgery; 
> had hearing problem that might hinder patient interview assessment; 
> had psychiatric or neurological disorders requiring chronic medication 
and were liable to prejudge patient adherence; 
> living in nursing home or old age home where drug administration might 
be aided by healthcare givers; 
> or referred to follow-up in clinics other than the three study clinics. 
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2.3 Patient recruitment 
Patient recruitment occurred during the period from 31 January 2003 to 12 
June 2003. Information on the recruitment process was provided to the nurses 
and pharmacists of the outpatient specialists clinics before the beginning of 
patient enrollment. (Appendix B1-B3) Two weeks prior to each clinic session, 
patient clinic schedules were obtained from the nurses in charge of the study 
clinics for screening of potential study patients. All patients were screened for 
the inclusion and exclusion criteria by reviewing their electronic patient records. 
Chinese adult patients currently on atorvastatin or simvastatin therapy for less 
than 12 months were first identified. Drug dispensing history was then checked 
to exclude patients who were being prescribed with other lipid-lowering agents 
in any public hospitals. Full history of diagnoses in the electronic records was 
also reviewed in order to assess the risk for CHD, and to identify patients with 
neurological disorders. Results of laboratory tests were inspected to identify 
patients who had documented fasting lipid profiles performed within one month 
before statins were initiated. Medical charts were scanned one day prior to the 
clinic visit, further excluding those who were participating in other clinical 
studies or attending the pharmacist-managed compliance checking clinic. 
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During clinic sessions, the short-listed patients were interviewed by the 
investigator (Cheng CWR) prior to medical consultation so as to exclude those 
who were living in nursing home or old age home, with hearing problems, or 
scheduled for elective surgery. Potential enrollees were informed and invited to 
participate in the observational study to investigate their drug-taking habit of 
statins and the control of cholesterol. Choice and dosage of the statin therapy 
prescribed were at the discretion of the primary care physicians. A 3-month 
supply of statin was dispensed in a bottle with the Medication Event Monitoring 
System (MEMS® 6 Trackcap, AARDEX Ltd., Zug, Switzerland) to those 
patients who provided written consent at the outpatient pharmacy. Atorvastatin 
and simvastatin were being used interchangeably at the public hospital, and 
patients were advised to take the drug every evening in order to avoid confusion. 
All study patients were scheduled for two follow-up clinic visits after 
recruitment at around month three and month six. 
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2.4 Assessments 
Patients' demographic information and clinical characteristics were 
collected at the entry of study. Two follow-up visits were scheduled at three and 
six months to monitor adherence to statin therapy. Fasting lipid profiles were 
obtained at entry of study and during the follow-up visits. (Appendix C) 
2.4.1 Adherence assessment 
2.4.1.1 Electronic monitoring 
The statin prescription was dispensed to the study patients in a bottle with 
a MEMS cap by a pharmacist at the entry of study and at the first follow-up visit. 
The patients were instructed to keep the statin tablets in the bottle and only open 
the bottle for taking the required quantity. The mechanism of the electronic 
monitor device was not disclosed unless the patients asked about the purpose of 
using the bottle. They were reminded to bring the bottle of unconsumed drugs 
back at the next follow-up visit. (Appendix D) Records in the MEMS were 
downloaded to a computer at each follow-up visit. Atorvastatin and simvastatin 
are used interchangeably per hospital policy. Patients were therefore advised to 
administer the drug from 18:00 to 00:00 to avoid confusion despite that the 
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regimens for atorvastatin and simvastatin were once daily (qd) and once every 
evening (qn) respectively. Adherence was presented in two dimensions: 
dose-count was defined as the percentage of times the bottle was opened over the 
monitored period, and dose-time was defined as the percentage of counts within 
the suggested time interval. Both measurements were categorized into 3 levels of 
adherence (Rudd 1994，Insull W 1997，Benner 2002): (1) Adherent patients are 
those with adherence of 80% or above; (2) partially adherent patients are those 
with adherence of 20%-79%; (3) Non-adherent patients are those with adherence 
< 20%. Partial adherence and non-adherence were classified as sub-optimal 
persistence. (Benner et al 2002) 
2.4.1.2 Patient report 
At each follow-up visit, a face-to-face interview was conducted in a 
private area by the investigator (Cheng CWR). Patients were asked about the 
number of days that they had missed or taken an extra dose and the usual time 
they took statin during the previous week. Dose-count adherence was presented 
in ordinal scales with four rankings (0 dose missed, 1 dose missed, 2 doses 
missed, and > 2 doses missed). Dose-time adherence reported by patients was 
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presented as either within suggested time interval or not within the interval. 
2.4.1.3 Pill count 
The number of doses left in the bottle was counted. Measurements assessed 
by pill count were continuous and were presented as percentage of tablets not 
returned by the patients: 
number of tablets dispensed - number of tablets returned ^ 湖。/ 
number of tablets dispensed 
2.4.1.4 Predictors of adherence 
Potential predictors of adherence assessed in the present study were 
demographic and clinical factors. Demographic factors included age, gender, 
smoking habit and socio-economic status. Clinical factors were the baseline 
co-morbidities including CHD events, stroke, congestive heart failure, diabetes 
mellitus, hypertension, obesity, serum LDL-C levels prior to statin therapy, the 
type and dosage of statin and number of other prescriptions at the entry of study. 
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2.4.2 Clinical outcome assessment 
2.4.2.1 Lipid control 
As LDL-C is the most predictive factor for CHD and also is the target for 
lipid control, it was chosen as the primary clinical outcome for the present study. 
Fasting lipid profiles were obtained at the entry of study and at each follow-up 
visit. The NCEP ATP III targets for lipid control were adopted by the chemical 
pathology laboratory of the Prince of Wales Hospital since 11 July 2002. 
Therefore, ATP III guidelines were adopted to determine the target level of 
LDL-C in the present study. Percent reduction in LDL-C was calculated from 
patients' baseline LDL-C measured prior to statin initiation. Since all study 
patients belonged to the group at high risk for CHD, their treatment goal for 
LDL-C was 2.6 mmol/L per ATP III guidelines. 
2.4.3 Economic outcome assessment 
2.4.3.1 Total direct medical cost 
Total direct medical cost over the monitored period was calculated for each 
study patient from the perspective of a public healthcare provider. The cost items 
included clinic visits, statin medications, laboratory tests on lipids and 
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management of CHD events if any. Since the majority of public healthcare 
services are provided by the Hospital Authority, it was both the payer and the 
provider of public healthcare services in Hong Kong. Costs of drugs were 
obtained from the electronic dispensing records. Costs for other items were 
based on the charges for public hospitals listed in Hong Kong Gazette 2003, 
assuming that the charges represent only the cost components (including labour 
costs) with no addition of profits. (Appendix E) 
2.4.3.2 Healthcare cost per member per month 
As there were variations in the duration between follow-up visits, healthcare 
cost per member per month (PMPM) was calculated using the following 
equation: 
, , , m … ， ， ” " � total direct medical cost (HKD) 
healthcare cost PMPM (HKD) = — ^ 
study duration of the patient (month) 
2.5 Sample size 
Adherence level to statin therapy estimated from previous study was 64.3 ± 
29.8%. (Avorn et al 1998) To achieve a 95% confidence interval, iaii was taken 
to be 1.96. The sample size required for determining the adherence with a 
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(1 96 X 29 8) 2 
standard deviation (SD) of 土 6.5% was therefore — ? = 81 subjects. In 
6.5 
order to account for possible patient drop-outs, it was decided that at least 100 
patients should be recruited. 
2.6 Statistical analysis 
Analyses were performed by Microsoft Excel (Microsoft Office 2000 
Professional, Microsoft Corporation, Washington, USA) and SPSS for Windows 
version 11.5 (SPSS Inc., Chicago, Illinois, USA). Descriptive statistics of patient 
demographics, dose-count and dose-time adherence and changes in serum 
LDL-C were reported. Data were presented in mean 土 SD or median with the 
25出 to 75th percentile, where appropriate. The adherence rates were significantly 
skewed (p<0.001) and failed to be normalized by square-root-transformation, 
logarithm-transformation or arcsin-transformation. Non-parametric analyses 
were therefore conducted. The correlations of MEMS dose-time and pill count to 
MEMS dose-count were expressed in terms of Spearman's rho coefficient (rs). 
Kruskal-Wallis rank test was used to detect the difference in MEMS 
measurements among the four sub-groups ranked by patient report. 
Mann-Whitney test was performed to determine if there was significant 
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difference in MEMS readings between patients who reported to consume the 
drug within the suggested time interval and those who did not. 
Adherence measured by MEMS was used as a continuous variable in the 
regression analysis. Backward multiple regression analysis was performed using 
probability of F statistics < 0.05 for entry and > 0.10 for removal to identify 
predictors for adherence, and to identify influential factors for cost PMPM. 
Models with maximum adjusted R^ were chosen. Unstandardized relative risk 
(RR) and 95% confidence interval (CI) were calculated from the parameter 
estimates (jS), using RR=e气 Linear regression analysis was used to test the 
relationship between adherence level and percentage LDL-C reduction, and R^ 
was the coefficient of determination. The difference in dosage of statin, baseline 
LDL-C, dose-count adherence, and reduction in LDL-C between atorvastatin 
users and simvastatin users were tested by Student's 广test or Mann-Whitney test, 
where appropriate. Type I error was set at 0.05 level and p-value <0.05 was 
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3.1 Study sample 
Between January and June 2003，the electronic records of 6326 patients 
from the three study clinics were screened. A total of 158 potential study patients 
were identified prior to their scheduled clinic visits. During the clinic sessions, 
15 patients were absent and 24 patients could not be reached owing to the busy 
clinic setting. By 12 June 2003，119 patients were informed and invited to 
participate in the present study. Eleven patients refused to participate and one 
patient insisted on using a pill-box. Five patients were referred to clinics other 
than the study clinics after physician consultation. A total of 102 patients 
provided written consent and were included in the study. 
One patient lost follow-up because he was admitted to a hospital due to 
tuberculosis and then transferred to old age home 1 month after recruitment. 
Among the 101 subjects, 15 patients transferred the statin tablets from the bottles 
to their own pill-boxes and three other patients did not close the MEMS bottles 
properly (caps were not completely closed when bottles were returned, with dose 
count recorded by MEMS <5%). Consequentially, analyses were based on the 83 
patients who had completed the study. The average follow-up period was 6 ± 1.2 
months. None of the study patients asked about the purpose of using MEMS and 
no adverse reaction was reported throughout the study. 
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3.1.1 Demographic characteristics 
Characteristics of the study patients were listed in Table 3-1. Mean age of 
the patients was 60 土 12.5 years and 51 (61%) of the patients were male. Forty-
six (55%) patients received simvastatin and 37 (45%) of them received 
atorvastatin. The mean simvastatin-equivalent daily dosage (5mg atorvastatin = 
lOmg simvastatin) prescribed was 16.5 土 6.4 mg. (Jones 1998) Patients on 
atorvastatin received significantly higher mean simvastatin-equivalent daily dose 
than those patients on simvastatin (19.2 土 4.9mg and 14.3 土 6.7mg respectively, 
pO.OOl). The average duration of statin therapy prior to the study was 6.9 ±3.2 
months and 35 patients (42%) of the patients were within their first 6 months of 
statin therapy. The average number of concurrent medications at recruitment was 
5 土 1.6 items. 
Table 3-1. Demographic data of study patients 
Characteristics Number (%) 
Number of patients 83 
Age in years (mean 土 SD) 60 土 12.5 
Male 51(61) 
Statin prescribed Simvastatin 46 (55) 
Atorvastatin 37 (45) 
Duration of statin therapy in months (mean 土 SD) 6.9 土 3.2 
Within first 6 months of statin therapy 35 (42) 
Number of concurrent medications (mean 土 SD) 5 ± 1.6 
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Education 
<6 years 42 (51) 
6-12 years 34(41) 
>12 years 7(8) 
Monthly household income (HKD)^ 




>25,000 13 (16) 
a: 1 USD = 7.8 HKD “ 
3.1.2 Co-morbidity factors 
Forty-nine patients (59%) had a diagnosis of diabetes mellitus and it was 
the most common CHD risk factor in this cohort (Table 3-2). Among the patients 
with diabetes, 34 (69%) of them did not have other CHD risk factors and nine 
(18%) of them had hypertension only. The most common CHD events 
documented were acute myocardial infarction and angina; the most frequent 
procedure done was percutaneous transluminal coronary angioplasty. 
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Table 3-2. Clinical characteristics of study patients 
Characteristics Number (Vof 
Co-morbidity 
Diabetes mellitus 49 (59) 
Acute myocardial infarction 19 (23) 
Hypertension 17 (20) 
Angina 15(19) 
Congestive heart failure 3 (4) 
Coronary atherosclerosis 3 (4) 
Stroke 1 (1.2) 
Procedure done 
PTCAb 23 (27) 
CABGe 3 (4) 
a: Sum of percentages for underlying risk factors exceeded 100 because some 
patients had multiple risk factors 
b: PTC A = Percutaneous transluminal coronary angioplasty 
c: CABG = Coronary artery bypass graft 
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3.2 Adherence measurement 
3.2.1 Electronic monitoring 
The adherence levels recorded by the electronic device were significantly 
skewed (p<0.001), these variables were therefore presented in median with 25*'^ -
75th percentile (Figure 3-1). 
Figure 3-1. Distribution of adherence measured by MEMS 
120 % -I  
100 % . . 
I I ‘ 
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20 % - + 
0 - ———— 
_ • 
dose-count dose-time 
95.3 % 78 2 % 
C25化-75，percentiles) (87.3-99.0%) (16 9-91 .8%) 
The median values of dose-count and dose-time adherence were 95.3% 
(25th-75th percentile: 87.3%-99.0%) and 78.2% (25出-751卜 percentile- 16.9%-
91.8%) respectively. There was no significant difference in the dose-count 
adherence between atorvastatin users (median: 96.2%) and simvastatin users 
(median: 95.3%). 
Distribution of study patients among adherent, partial adherent and non-
adherent was shown in the table 3-3. According to the criteria defined previously, 
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seventy patients (84%) and 39 patients (47%) were considered as adherent to 
dose-count and dose-time correspondingly. 
Table 3-3. Patient distribution in three levels of adherence measured by 
MEMS 
Number of patients (%) 
Adherence Level Dose-count Dose-time 
Adherent (> 80%) 70 (84.3) 39 (47.0) 
Partial adherent (20%-79%) 12 (14.5) 22 (26.5) 
Non-adherent (< 20%) 1 (1.2) 22 (26.5) 
3.2.2 Patient report 
The adherence level to dose-count measured by patient report was 
significantly skewed (pO.OOl). The median of adherence rate reported by 
patients was 100.0% percentile = 98.8%-100.0%). Eighty patients 
(96%) had dose-count adherence rate of at least 80%. Results of patient report 
classified subjects into four sub-groups and the majority of patients reported 0 
dose missed in the previous week (Table 3-4). Sixty-one patients (74%) reported 
that they were taking statins within the suggested time interval. 
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Table 3-4. Adherence measured by patient report and electronic device 
Median of MEMS^ readings 
Dose-count reported by patients No. of patients (%) Dose-count Dose-time 
0 dose missed 53 (64) 
1 dose missed 27 (33) 88 % 
2 doses missed 2 (2) 74 % 
> 2 doses missed 1(1) 3 % 
p-valuec 0.022 
Dose-time reported by patients 
Within time interval^ 61 (73) 87 % 
Outside time interval 22 (27) 4 % 
p-value' < 0.001 
a: MEMS = Medication event monitoring system 
b :Time interval = 18:00-00:00 for statin administration 
c: p<0.05 was considered as statistically significant 
3.2.3 Pill Count 
The adherence level measured by pill count was also significantly skewed 
(p<0.001). The median of adherence rate measured by pill count was 99.0% 
(25th•乃th percentile = 96.4%-100.0%). Moreover, eighty patients (96.4%) had 
adherence rate of 80% or higher. 
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Figure 3-2. Scatter-plot of relationships among methods for measuring 
adherence 
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3.2.4 Correlation among methods for measuring patient adherence 
Correlation between dose-count and dose-time adherence measured by 
MEMS was 0.43 (p<0.001). Although adherence measured by patient report and 
pill count were higher than those recorded by the electronic monitoring device, 
mild correlations among patient adherence assessment methods were noticed 
using the electronic monitoring device as the validation standard. As shown in 
table 3-4，adherence measurements by MEMS among the four sub-groups 
classified by patient report were significantly different for dose-count adherence 
(p=0.022) and dose-time adherence (p<0.001). A low correlation of pill count 
with electronic monitoring was observed (rs=0.37, pO.OOl). 
47 
Chapter 3 Results 
3.2.5 Trend of adherence and persistence over time 
By grouping the MEMS dose-count and dose-time adherence 
measurements into the three clusters (0-3 months, 3-6 months and > 6 months), 
the pattern of median adherence to statin therapy over time was presented in 
Figure 3-3. Both dose-count and dose-time adherence declined noticeably over 
the first six months of therapy. The adherence to dose-count normalized from 
111% during the first 3 months to 98% during the next 3 months and then 
became stable at 96% beyond the 6…month of satin therapy. Dose-time 
adherence also showed a decline during the first 6 months from 89% in the first 
quarter to 80% in the second quarter, and became 79% afterwards. 
Figure 3-3. Trend of adherence to statin therapy over time 
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Similarly, the percentages of patients with adherence rates >80% were 
grouped by the month of therapy since initiation. As shown in figure 3-4，the 
number of patients being persistent on dose-count of statin therapy declined over 
time, from 100% to 88% and then 62% during the treatment. 
Figure 3-4. Trend of persistence in the use of statins over time 
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3.2.6 Independent predictors of adherence 
Predictors of adherence identified by backward multiple regression 
analysis were shown in Table 3-5. Twelve factors were associated to MEMS 
dose-count adherence and three of them achieved statistical significance 
(R2=0.254’ P=0.039). RR and 95% CI were calculated by RR=e义 Living with 
family (RR=0.786, 95% CI=0.6630-0.9315) and duration of therapy (RR=0.988， 
95% CI=0.9773-0.9999) were negative predictors while number of family 
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members among those living with family (RR= 1.045, 95% CI=1.0090-1.0811) 
was a positive predictor for adherence to dose-count. R^ of the model on dose-
time adherence was 0.238 (p=0.014). Among the five factors associated with 
MEMS dose-time adherence, monthly household income (RR=1.010, 95% 
CI= 1.0020-1.0171) and angina (RR=1.288, 95% CI=1.0502-1.5809) were 
positive predictors while living with family (RR=0.736, 95% 0=0.5477-0.9900) 
was a negative predictor for dose-time adherence. 
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Table 3-5. Association between potential predictors and percent change 
of adherence to statin therapy 
Predictors' RR (95% CI)" p-value' 
Dose- Living with family 0.786 (0.6630-0.9315) 0,006 
count 
Number of family members 1.045 (1.0090-1.0811) 0.0J3 
Duration of therapy (month) 0.988 (0.9773-0.9999) 0,048 
Congestive heart failure 0.832 (0.6730-1.0284) 0.088 
Retired 1.050(0.9714-1.1366) 0.213 
Baseline LDL-C^ prior to therapy 0.977 (0.9296-1.0274) 0.353 
(mmol/L) 
Number of current medications 0.988 (0.9618-1.0141) 0.358 
Stroke 1.164 (0.8344-1.6258) 0.366 
Male 0.971 (0.9493-1.1152) 0.476 
Smoker 0.960 (0.8521-1.0800) 0.491 
Hypertension 0.970 (0.8763-1.0714) 0.535 
Diabetes mellitus 0.976 (0.9012-1.0576) 0.547 
Dose- Monthly household income 1.010 (1.0020-1.0171) 0.015 
time (thousand HKDf 
Angina 1.288 (1.0502-1.5809) 0.016 
Living with family 0.736 (0.5477-0.9900) 0.043 
Stroke 1.711 (0.8403-3.4834) 0.137 
PTCAf 0.895 (0.7445-1.0757) 0.232 
a: Number of family members, duration of therapy, baseline LDL-C prior to 
therapy, number of current medications and monthly household income were 
continuous variables 
b: Unstandardized relative risk and respective 95% confidence interval 
c: p<0.05 was considered as statistically significant 
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d: LDL-C = Low-density lipoprotein cholesterol 
e: 1 USD = 7.8 HKD 
f: PTCA = Percutaneous transluminal coronary angioplasty 
3.3 Outcome assessment 
3.3.1 Clinical outcomes 
Thirty-seven patients (45%) were prescribed with atorvastatin while 46 
patients (55%) were on simvastatin. The baseline serum LDL-C before initiation 
of statin therapy was 3.85 土 0.73 mmol/L (atorvastatin users: 3.82 土 0.68 
mmol/L, simvastatin users: 3.88 土 0.78 mmol/L, p=0.909). The average 
reduction in serum LDL-C by the end of the study was 39 土 14.4o/o. There was 
no significant difference between atorvastatin users and simvastatin users in 
LDL-C reduction (40.4 土 16.3% and 38.5 土 13.1%, respectively). The mean level 
of serum LDL-C was 2.3 土 0.6 mmol/L and 63 patients (76%) achieved the 
target LDL-C of 2.6 mmol/L (Anonymous 2001) by the end of the study. 
3.3.2 Economic outcomes 
Three (4%) patients had documented CHD events during the study period. 
The respective CHD-related total direct medical cost and cost PMPM were 
calculated for each study patient from the public health provider's perspective. 
Median of the total direct medical cost (1 USD = 7.8 HKD) of the three patients 
who had experienced CHD was HKD 23,296 (range: HKD 20,248 - 44,821). The 
average monthly healthcare cost, cost PMPM, of all 83 patients (with and 
without CHD events) ranged from HKD 191 to 7,167, with median of HKD 333. 
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For the 80 (96%) patients without CHD event recorded during the study period, 
median cost PMPM was HKD 331 (25出—75出 percentile = HKD 297 - 347). For 
the three (4%) patients experienced CHD events, median cost PMPM was HKD 
3,461 (range: HKD 3,288 - 7,167). By Mann-Whitney test, there was statistical 
significant difference in the cost PMPM between the patients with and without 
CHD event (p=0.003). 
3.4 Association between adherence and clinical outcomes 
3.4.1 Adherence and LDL-C reduction 
Linear regression models between adherence levels and percentage 
reduction in LDL-C were statistically significant as shown in table 3-6 (dose-
count: p<0.001 and dose-time: p=0.047). R^was the coefficient of determination, 
which represented the proportion of variability explained by the independent 
variable. 
Table 3-6. Association between patient adherence to statin therapy and 
percent reduction in LDL-C 
Regression models^ 
1 X i8o (3i R r2 p-value 
% 
Reduction Dose-count 0.118 0.308 0.361 0.130 0.001 
in 
LDL-C Dose-time 0.344 0.083 0,261 0.048 0.047 
a: y = + yffi X 
b: p<0.05 was considered as statistically significant 
c: LDL-C = Low-density lipoprotein cholesterol 
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About 13% variability in the reduction of LDL-C could be explained by 
dose-count adherence to statins, while dose-time adherence contributed to only 
4.8% of the variation (R^ =0.130 and 0.048 accordingly). The changes of percent 
reduction in serum LDL-C against adherence of dose-count and dose-time were 
shown on Figure 3-5. Weak correlation of 60% dose-count adherence to 30% 
reduction in LDL-C was shown. 
Figure 3-5. The change of percent reduction in serum LDL-C against 
adherence to statins 
Reduction in 
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3.4.2 Adherence and NCEP ATP III target 
Sixty-three patients (76%) achieved NCEP ATP III target for LDL-C 
reduction by the end of the study. Patients who achieved target LDL-C showed 
slightly higher dose-count (96.4% versus 94.6%, p=0.092) and dose-time (79.6% 
versus 64.8%, p=0.294) adherence to statins than those who did not achieve the 
target despite the statistically insignificant results. 
3.5 Association between adherence and economic outcomes 
3.5.1 Adherence and healthcare utilization 
Median dose-count adherence of those three patients experienced CHD 
events was 96.4% (range: 85.9%-98.8%), and their dose-time adherence was 
88.1% (range: 24.7%-92.9%). Median and percentile for dose-count and 
dose-time adherence of the study patients who did not experience CHD events 
were 95.3% (87.5%-99.0%) and 77.2% (13.8%-91.6%), correspondingly. Dose-
count adherence and dose-time adherence measured by MEMS were not 
significantly associated with the occurrence of CHD events (p=0.951 and 
p=0.660, respectively). Association between adherence levels and healthcare 
utilization in terms of cost PMPM was determined by backward multiple 
regression, controlling for other covariates. The model with maximum adjusted 
r2 was chosen, which was also statistically significant (R^=0.65, p<0.001). Nine 
important covariates identified were gender, monthly household income, primary 
education (< 6 years), dose-time adherence to statins, history of diabetes mellitus, 
congestive heart failure, coronary atherosclerosis, coronary artery bypass graft 
and percutaneous transluminal coronary angioplasty (Table 3-7). Four of them 
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were statistically significant that male gender, history of diabetes mellitus, 
congestive heart failure and coronary atherosclerosis seemed to be associated 
with higher consumption of healthcare resources. 
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Table 3-7. Association between cost PMPM and covariates of statin 
therapy 
Covariates' (3 (95% CI)b p-value� 
Cost Congestive heart failure 1957.3 (1006.0-2908.5)<0.001 
PMPMd 
Male 583.8 (215.1-952.4) 0.002 
Coronary atherosclerosis 1436.0 (537.8-2334.1) 0.002 
Diabetes mellitus 603.7 (136.0-1071.4) 0.012 
Primary educated 317.1 (-37.3-671.5) 0.079 
Monthly household income -14.9 (-32.3-2.5) 0.092 
(thousand HKDf 
PTCAf 341.0 (-180.8-862.9) 0.197 
Dose-time adherence 279.5 (-155.9-715.0) 0.205 
CABG® 549.5 (-399.8-1498.7) 0.252 
a: Monthly household incomes and dose-time adherence were continuous 
variables 
b: Unstandardized parameter estimate and respective 95% confidence interval 
c: p<0.05 was considered as statistically significant 
d: PMPM = Per member per month 
e: 1 USD = 7.8 HKD 
f: PTCA = Percutaneous transluminal coronary angioplasty 
g: CABG = Coronary artery bypass graft 
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Chapter 4 Discussion and Conclusion 
4.1 Discussion 
4.1.1 Accuracy of patient report and pill count 
Poor patient adherence may involve delay in seeking care, breaking of 
appointment, failure to follow physician's instruction or to fill prescriptions, 
missing doses, self-adjustment of dose or time of administration, and 
self-termination of treatment. (Insull 1997, Vermeire et al 2001) Improving 
adherence to prescribed medication is one of the major responsibilities of 
pharmacists. A better understanding of the pattern of patient adherence would 
enhance the design and implementation of pharmacy intervention for patients 
with poor adherence. 
Deviation from the recommended timing of administration was greater 
than the amount of drugs administered. Choo et al (1999) had conducted a 
validation study of patient report, pharmacy dispensing records and pill count 
against electronic monitoring among 286 patients on monotherapy for 
hypertension. MEMS dose-count and dose-time adherence over three months 
were 92% and 63% respectively, and the correlation between the two 
measurements was 0.32. In the present study, low correlation was observed 
between dose-count and dose-time assessed by MEMS (rs=0.43), which was 
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similar to the previously reported findings. 
Studies had shown that pill count allowed patients to manipulate the data 
by storing of unused drugs for future use or discarding the unused medications 
before clinic visits and it therefore over-estimated adherence. Pullar et al (1989) 
reported that 32% of patients who appeared to have good adherence by returned 
tablet count were suggested to have poor adherence by a pharmacological 
indicator. It had also been reported that pill count adherence was marginally 
correlated to dose-count by MEMS among patients receiving antihypertensive 
agents (r=0.24-0.52). (Rudd et al 1990, Choo et al 1999) Liu et al (2001) 
assessed pill count of 108 patients naive to protease inhibitors or had started on 
therapy in the past three months. Significant but mild correlation was found 
between MEMS and pill count (r=0.46, p<0.001). In our cohort of patients on 
statins, low correlation between electronic monitoring and pill count was 
observed (rs=0.37, p<0.001) which was also similar to the previous findings. 
Comparing patient report adherence to MEMS adherence, our findings 
supported the results of previous studies on antiretroviral therapy adherence that 
patient report adherence was consistently higher than the adherence recorded by 
electronic monitoring. In the study of Liu et al (2001), patient report provided 
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the highest estimate of adherence to antiretroviral therapy (93 土 14o/o) when 
MEMS measurements showed 63 + 31%. Similarly, patient report of 173 patients 
with AIDS showed high adherence of 93.7% while their electronic monitoring 
devices revealed moderate adherence of 80.6%. (Wagner 2002) 
Patient report in the present cohort seems to be sensitive to changes in 
both dose-count and dose-time adherence that patients reporting higher 
adherence rates to the number of doses administered and to the timing of dosing 
were having significantly higher MEMS readings (p=0.022 and <0.001 
correspondingly). Our findings are consistent with the results of previous studies. 
Correlations between MEMS and patient report adherence to antiretroviral 
agents were reported to be marginal. In a 6-month observational study of 67 
antiretroviral agent users, Amsten et al (2001) stated that patient adherence 
measured by self-report for 1-week and by MEMS were mildly correlated 
(r=0.46, p<0.001). Other studies also showed similar correlation levels (r=0.34 in 
Wagner 2002 and r=0.38 in Liu et al 2001). 
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4.1.2 Persistence to statin therapy over time 
Results of the present study revealed that, in the present cohort of Chinese 
patients at high risk for CHD, the observed dose-count was over 100% during 
the first few months of treatment, and adherence to statins tended to normalize 
from the third month onwards. From the first 3 months of therapy to the next 
quarter, the adherence to both dose-count and dose-time decreased by 10%, and 
by 2% from the quarter to 6 months after. The rate of decline of adherence to 
statin therapy reported in a Danish study was similar to that of the present study. 
Larsen et al (2002) reviewed the statin prescription filling records of 3,623 
patients in Denmark from 1993 to 1998. The fraction of statin users remained in 
treatment declined from 100% to 75% after 10 months of treatment. In a US 
study, Benner et al (2002) reported that adherence to statin prescription filling, in 
a cohort of 34,501 patients who were 65 years of age of older, declined 
substantially over time especially in the first six months. The proportion of 
patients who were adherent with statin therapy was 79%, 56%, and 50% after 3, 
6，and 12 months, respectively. The persistently high adherence rate observed in 
the present study could be explained by the fact that the study cohort who 
provided written consent might be more adherent than those refused to 
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participate in the study. Also, all the study patients had CHD-equivalent risk or a 
history of CHD events, and, CHD indicators were identified as negative 
predictors of sub-optimal persistence. (Benner et al 2002) In the present study, 
no patient asked about the purpose of using the bottle with MEMS cap and the 
measurement of adherence was therefore unlikely to be affected by the electronic 
monitoring device. 
4.1.3 Predictors for patient adherence 
Possible predictors identified from our study cohort included living with 
family, number of family members, duration of therapy, monthly household 
income and documented angina pectoris. Opposite effects of living with family 
and number of family members on adherence to dose-count was observed in the 
present study. Living with family was found as a negative predictor for 
dose-count adherence. Adherence among patients living with their families were 
around 0.8 times to those who were living alone. Wagner (2002) also reported 
similar findings that living alone was significantly associated with greater 
adherence to antiretroviral medications as measured by both electronic 
monitoring and patient report. Apparently, study patients who were not living in 
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nursing home, old age home nor with their families were better adherent to statin 
therapy than those who were living with their families. McLane et al (1995) 
reported that elderly patients who were living alone showed significantly higher 
adherence to antihypertensive medications than those who were living with 
spouse or others (p=0.04). It was suggested that patients living alone are more 
adherent to treatment because they may realize that their health is their own 
responsibility. Nevertheless, adherence to dose-count increased with the number 
of family members among those patients who were living with family 
(RR= 1.045 for each additional family member). Our results were consistent with 
previous reports that the number of close family members was significantly 
associated with the amount of household care received by the elderly patients 
and the elderly responded positively to their own health declines in a family with 
more adult members. (Chou and Chi 2001, Kaneda 2003) In a meta-analysis, 
adherence could be 1.74 times higher in patients from cohesive families but 1.53 
times lower among those from families in conflict. (DiMatteo et al 2004) The 
positive effect of number of family members on patient adherence showed in our 
cohort might be explained by better family support from cohesive families. 
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Monthly household income was a statistically significant positive 
predictor for statin adherence, despite that its effect was minimal. An increase in 
HKD 1,000 corresponded to approximately 1% increase in adherence 
(RR=1.010). As suggested previously, patients with present CHD risk indicators 
may be better adherents. Angina was the only CHD risk factor found to be 
significantly associated with high adherence in the present cohort. Patients with 
history of angina were 1.288 times more adherent to the prescription than those 
without angina. Since only one patient had a history of stroke, no conclusions 
regarding the association between stroke and adherence could be drawn. 
Our findings of high adherence to statin therapy in the present cohort 
(mean age: 60 ± 12.5 years) agreed with the previous reports that elderly patients 
aged 60 years or older were better adherent, whereas those under 45 years or 
over 75 years old showed significantly lower adherence rates. (Kiortsis et al 
2000, Benner et al 2002) Despite the fact that most of the study patients were 
elderly and all of them were Chinese, none of them showed difficulty in 
understanding the instructions of the investigator during recruitment. Of the 102 
patients recruited, less than 20% of them (19 patients) failed to follow the 
instructions and were excluded from data analysis. The effect of Chinese culture 
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on medication adherence was examined in a few surveys for patients receiving 
hormone replacement and antiretroviral agents and Chinese patients seem to 
have high levels of adherence to drug therapy. The 5-year adherence to hormone 
replacement therapy among Hong Kong Chinese post-menopausal women was 
71.1%. (Leung et al 2001) Adherence to antiretroviral agents was high in 
Chinese patients that only 1.9% patients reported taking <90% of the drugs. 
(Molassiotis et al 2002, Fong et al 2003) 
4.1.4 Clinical impacts of patient adherence 
Comparing to the findings of overseas clinical trials, more patients (76%) 
achieved the target LDL-C in the present study and a lower level of adherence 
(>60%) was weakly correlated ( r M . 1 3 ) to the target LDL-C reduction (30%). 
An analysis of the effect of pravastatin reported that higher level of adherence 
(>75%) was required to demonstrate substantial CHD risk reductions in 
comparison with that achieved an intention-to-treat analysis. (Anonymous 1997) 
Despite that the level of adherence to pravastatin observed in Sweden was well 
above 90%, less than 20% patients achieved the target total cholesterol of 5.2 
mmol/L. (Eriksson et al 1998) Comparing to Western populations, the lower 
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level of adherence correlated to target cholesterol reduction may be explained by 
the lower baseline LDL-C level in Chinese population. (Tomlinson 2001) The 
baseline LDL-C prior to statin therapy in the present Chinese cohort (3.85 
mmol/L) was significantly lower (pO.OOl) than the baseline LDL-C in 4S(4.87 
mmol/L) and the Swedish study (5.5 mmol/L). (4S Study group 1994，Eriksson 
et al 1998) Although Asians share similar CHD risk factors with Caucasians, 
lower doses of lipid-lowering drugs were reported to achieve the same target 
lipid level. Itoh et al (1997) found that a low dose of simvastatin (5 mg qn) 
decreased LDL-C by 21.1 Vq in 201 Japanese patients. Our study also found a 
lower mean statin dosage (equivalent to simvastatin 16.5 mg) being used in the 
present Chinese cohort compared to the usual starting dose of simvastatin (20-40 
mg) as used in 4S, (4S Study group 1994，Merck & Co., 2004) yet comparable 
LDL-C reduction was achieved (39% in the present study and 35% in 4S). In the 
Simvastatin Treats Asian to Target (STATT) study, 72.2% of the 133 patients 
achieved NCEP ATP III target (LDL-C of 2.6 mmol/L) by a daily simvastatin 
dose of 20 mg. The mean daily dose of simvastatin required to achieve the same 
target LDL-C level was 27.5 mg per day. (Chung et al 2001) Our results 
supported the findings of STATT that the Chinese patients may be more sensitive 
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to Statin therapy, and this hypothesis needs to be confirmed prospectively. The 
Chinese diet is lower in total fat, saturated and trans fatty acid than the Western 
diet, and such diversity in dietary habit may also contribute to the better clinical 
response to statin therapy among Chinese. (Woo et al 1998，Zhou et al 2003) 
4.1.5 Economic impacts of patient adherence 
Various studies have shown that statins are cost-effective in the secondary 
prevention of CHD, when compared with other lipid-modifying therapies. (Oster 
et al 1996, Johannesson et al 1997，Black et al 1997，Koren et al 1998，Huse et 
al 1998) Findings reported by Caro et al (1999) based on WOSCOPS data 
suggested that the cost of using pravastatin therapy as primary prevention should 
also be acceptable in most countries. However, few studies have accounted for 
the impact of non-adherence and partial adherence to the use of statins. In a 
Markov model analysis investigating the cost-effectiveness of statins for 
secondary prevention of CHD based on the non-adherence rates established for 
4,948 Irish patients, non-adherence increased the incremental cost-effectiveness 
ratios from 1,172-3,900 Euro per quality-adjusted life-year (QALY) to 
2,388-7,508 Euro/QALY. (Heerey and Barry 2002) 
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Total direct medical cost was calculated for each study patient from the 
public healthcare provider's perspective. Patients with CHD events occurred 
during the monitored period that lead to subsequent hospital admissions yielded 
markedly higher healthcare cost PMPM than those without CHD episodes. 
Covariates with statistically significant association to healthcare utilization in 
terms of cost PMPM was identified. The covariates chosen by backward multiple 
regression were able to explain for 65% of the variability in cost PMPM. Male 
gender, history of diabetes, congestive heart failure and coronary atherosclerosis 
were related to higher consumption of healthcare resources. Dose-time adherence 
to statins, monthly household income, primary education and cardiac procedures 
done in the past seemed to contribute very little to economic outcomes. The cost 
PMPM associated with statin therapy was mainly driven by the cost for 
management of CHD events. Correlation between patient adherence to statin 
therapy and healthcare cost PMPM was not observed in the present study, 
possibly because very few patients experienced CHD events during the study 
period and that the adherence data clustered about 100%. 
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4.1.6 Limitations 
In the present study, the electronic monitoring device was assumed to be 
a reliable standard for examining the accuracy of patient report and pill count. It 
was limited by the possibility that patients might have forgotten to close the cap 
in a timely manner during drug administration, thereby under-estimating the 
number of drug-taking events. Although the MEMS cannot prove direct 
consumption of the drug, prolonged deception by the patients has been shown to 
be unlikely since such behavior was difficult to maintain over long period of 
time. (Kastrissos et al 1998) In the present study, no patient asked about the 
purpose of using the bottle with MEMS cap and thus the measurement of MEMS 
was unlikely to be affected by direct electronic monitoring. 
The present study might be limited by selection bias in the patient 
screening process that majority of enrollees who gave consent to participate in 
the study might be more motivated to adhere with statin therapy, whereas 
patients who refused to participate in the study were more likely to have lower 
adherence. Recruitment refusal was 9% and those patients might be potential 
non-adherents or partial adherents. The present study was also limited by a small 
sample size of 83 patients. Very few poor adherents were observed in the present 
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cohort thus the distribution of adherence rates were heavily skewed. The heavily 
skewed data failed to be normalized by transformations, thus the power of linear 
regression was weakened. The low level of correlations observed between 
adherence and the interested outcomes may be caused by the fact that most of the 
adherence data points clustered near 100%. 
4.2 Conclusion 
Patient report and pill count over-estimated patient adherence to statin 
therapy in a cohort of elderly Chinese patients at high risk of CHD. Patient report 
was sensitive to changes of both dose-count and dose-time adherence measured 
by the electronic monitoring device while the correlation of pill count adherence 
to MEMS adherence was low. Patient report appeared to be a more accurate tool 
than pill count for adherence assessment in clinical settings. 
High adherence to statin therapy was found in the present cohort and the 
adherence normalized over time. Number of family members and the presence of 
CHD risk indicators appeared to be influential to the extent of patient adherence 
to statin therapy. A weak association between adherence to statin dose-count and 
LDL-C reduction was found, and a marginal association between adherence to 
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dose-time and LDL-C reduction were observed. Patient adherence to statins was 
not significantly associated with healthcare utilization in the present cohort. A 
large long-term study would be necessary to confirm the findings of the present 
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A-1. Framingham risk scoring system for male 
20-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 
years years years years years years years years years years 
^ A 0 3 6 8 10 n 12 
TC (mg/dL) 
< 160 0 0 0 0 0 
160-199 4 3 2 1 0 
200-239 7 5 3 1 0 
240-279 9 6 4 2 1 
> 280 11 8 5 3 1 
Smoker 8 5 3 1 1 
Non-smoker 0 0 0 0 0 
SBpb (mniHg) If treated If untreated Total points 10-year risk (%) 
< 120 0 0 ^ 
120-129 1 0 ？ I 
130-139 2 1 2 1 
140-159 2 1 4 1 
> 160 3 2 5 2 
— 6 2 
7 3 
, 8 4 
HDL-C (mg/dL) g 5 
> 6 0 -1 10 6 
11 8 
50-59 0 12 10 
40-49 1 13 12 
14 16 
< 4 0 2 15 20 
16 25 
>17 >30 
a: TC = Total cholesterol 
b: SBP = Systolic blood pressure 
c: HDL-C = High-density lipoprotein cholesterol 
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A-2. Framingham risk scoring system for female 
20-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 
years years years years years years years years years years 
^ ^ 0 3 6 8 10 12 14 
TCa (mg/dL) 
< 160 0 0 0 0 0 
160-199 4 3 2 1 1 
200-239 8 6 4 2 1 
240-279 11 8 5 3 2 
>280 13 10 7 4 2 
Smoker 9 7 4 2 1 
Non-smoker 0 0 0 0 0 
SBP" (mmHg) If treated If untreated Total points 10-year risk (%) 
< 120 0 0 ^ 
120-129 3 1 i ; 。 J 
130-139 4 2 11 1 
140-159 5 3 I3 2 
> 160 6 4 14 2 
15 3 
16 4 
HDL-C (mg/dL) 14 5 
18 6 
>60 -1 19 g 
50-59 0 20 11 
21 14 
40-49 1 22 17 
< 4 0 2 23 22 
24 27 
>25 >30 
a: TC = Total cholesterol 
b: SBP = Systolic blood pressure 
c: HDL-C = High-density lipoprotein cholesterol 
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B-1. Information sheet provided to nurses of the Cardiology clinic 
Statins Adherence Study at Cardiology Clinic 
Nurse Information Sheet 
I Aims of the study： Summary of the study： 
j 1. To determine the correlations among different High CHD risk patients who are on statin 
methods of measuring adherence; monotherapy started within 12 months will be 
I 2 . To describe the trend of patient adherence with recruited. Patients' demographic and clinical i 
statins and to identify patient characteristics that information will be collected at the entry of study. I 
predict adherence in Chinese; The schedule of F/U visits is at the discretion of | 
I 3 . To examine the association of variable the primary care physician. Data on adherence | 
adherence with statins to the control of LDL-C; levels (measured by electronic device MEMS, pill 1 
I 4 . To examine the association of variable count and interview), changes in lipid profile and | 
adherence with statins to the healthcare utilization of healthcare resources will be collected | 
resources utilization and healthcare costs. from Jan 2003 to Mar 2004 for analysis. 
! I 
Responsible persons: Caroline Cheng, M.Phil student, SOP, CUHK 
Prof. Joyce You, SOP, CUHK 
Prof. KS Woo, Dept. Med & Therapeutics 
TWO WEEKS before clinic visit- 
(Jan2003 - June2003) �Carol ine obtain pulling list from OPD 
O N E DAY Caroline find medical charts of patient-to-be recruited 
before clinic visit 一 T 
Y  
(Jan2003 - Mar2004) | stick a label on the front cover 
Caroline collect labelled medical charts in the Tx Room 
5 
interview patient 
Or? the da l • New patient - to obtain informed consent OR 
2. F/U patient - to obtain patient adherence information 
of clinic visit -
(Thursday afternoon) i  
replace all medical charts as soon as possible  
y  
F/U note collected by nurse and 
signed by Prof. KS Woo 
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B-2. Information sheet provided to nurses of the Diabetes clinic 
Statins Adherence Study at Diabetes Clinic 
Nurse Information Sheet 
I Aims of the study: | Summary of the study: 
i 1. To determine the correlations among different | High CHD risk patients who are on statin 
methods of measuring adherence; | monotherapy started within 12 months will be 
I 2 . To describe the trend of patient adherence with i recruited. Patients' demographic and clinical I 
i statins and to identify patient characteristics that 1 information will be collected at the entry of study, i 
predict adherence in Chinese; j The schedule of F/U visits is at the discretion of | 
I 3 . To examine the association of variable adherence i the primary care physician. Data on compliance ! 
i with statins to the control of LDL-C; | levels (measured by electronic device MEMS, pill I 
j 4 . To examine the association of variable adherence j count and interview), changes in lipid profile and 1 
I with statins to the healthcare resources utilization i utilization of healthcare resources will be collected 1 
and healthcare costs. I from Jan 2003 to Mar 2004 for analysis, 
i 1 i 
Responsible persons: Caroline Cheng, M.Phil student, SOP, CUHK 
Prof. Joyce You, SOP, CUHK 
Prof. Juliana Chan, Dept. Med & Therapeutics 
TWO WEEKS before clinic visit -
(Jan2003 - June2003) Caroline borrow pulling list from OPD 
O N E D A Y Caroline find medical charts of patient-to-be recruited 
before clinic visit -
(Jan2003 - Mar2004) | stick a label on the front c o v l T " 
Caroline collect labelled medical charts in the Tx Room 
Y 
interview patient in Room 28/29, 1/F LKS 
0/7 the day 3 New patient 一 to obtain informed consent OR 
of clinic visit - 4. F/U patient - to obtain patient adherence information 
(Friday afternoon) ， 
replace all medical charts as soon as possible 
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B-3. Information sheet provided to nurses of the Lipid clinic 
Statins Adherence Study at Lipid Clinic 
Nurse Information Sheet 
i Aims of the study: i Summary of the study: 
I 1 . To determine the correlations among different 1 High CHD risk patients who are on statin 1 
methods of measuring adherence; i monotherapy started within 12 months will be | 
I 2 . To describe the trend of patient adherence with | recruited. Patients' demographic and clinical i 
statins and to identify patient characteristics that j information will be collected at the entry of study. | 
predict adherence in Chinese; i The schedule of F/U visits is at the discretion of | 
1 3 . To examine the association of variable adherence I the primary care physician. Data on compliance i 
with statins to the control of LDL-C; j levels (measured by electronic device MEMS, pill j 
I 4 . To examine the association of variable adherence j count and interview), changes in lipid profile and | 
with statins to the healthcare resources utilization | utilization of healthcare resources will be collected I 
and healthcare costs. i from Jan 2003 to Mar 2004 for analysis. 
i i I 
Responsible persons: Caroline Cheng, M.Phil student, SOP, CUHK 
Prof. Joyce You, SOP, CUHK 
Prof. Brian Tomlinson, Dept. Med & Therapeutics 
T W O W E E K S before clinic visit -
(Jan2003 — June2003) Caroline borrow pulling list from OPD 
o n e d a 丫 Caroline find medical charts of patient-to-be recruited 
before clinic visit -
Y  
(Jan2003 - Mar2004) | stick a label on the front c o v l T " 
Caroline collect labelled medical charts in the Tx Room 
y 
interview patient 
0 /7 the day l New patient 一 to obtain informed consent OR 
of clinic visit - 2. F/U patient - to obtain patient adherence information 
( M o n d a y morning) ， 
replace all medical charts as soon as possible 
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C. Data collection form 
Patient initial: M I F Age: Patient no.:  
Date of recruitment: 2003/ I Enrolled clinic: LC / CC / DM 
Demographic information 
1. Smoker / non-smoker / ex-smoker ( packs/day) 
2. Working status: unemployed / retired / working ( hrs/wk ) 
3. Educational level: • Primary or below • Secondary • Tertiary or 
above 
4. Living with family: Y/N , (independent / maid / special nurse ) 
5. Monthly household income: •<$8000 •$8000-$15000 
•$15000�$20000 •$20000-$25000 •>$25000 
Adherence measurements 
Date of F/U  
Interview 
Usual time of dosing  
No. of dose(s) missed/ 7 days 
No. of extra dose(s) 17 days 
Last missed 
Reason {+/-) 
% dose-count adherence  
Pill count 
No. of tablets prescribed 
Expected no. of tablets left 
Actual no. of tablets left 





History of disease(s): 
Co-morbidities: 
• DM • AMI • CABG 
• HTN • CHF • PTCA 
• obesity • angina pectoris • stent 
• • stroke • 
• • coronary atherosclerosis • 
Others: 
Current medication(s): 





Baseline LDL-C( )mmol/L   





% reduction in LDL-C 
92 
Appendices 
Healthcare resources consumptionfs) 




D. Instruction sheet provided to the study patients 
Instructions for pill bottle 
V Please bring this bottle with you at the next clinic visit. 
Z Please close the cap tightly after taking out the tablet. 
Z You are not required to cut the tablet. 
V Please store this bottle in a cool and dry place. 
* Do not open this bottle unless it is time to take medication. 
* Do not transfer the tablets to other containers. 
* Do not put other drugs into this bottle. 
！ Keep out of reach of children or other persons. 
For enquiries, please con tac t School of Pharmacy, CUHK 
(Tel: 2609 6830) 
藥罐使用說明 
Z 請 於 下 次 覆 診 時 把 此 藥 罐 一 倂 帶 回 。 
Z每次服藥時，請於取出所需藥片後隨即把藥罐關緊。 









E. Unit cost of items from electronic dispensing record and 
Hong Kong Gazette 2003 for estimating total direct medical cost 
Cost items Unit cost (HKDf 
Medication 
Atorvastatin 5 mg 3.41 
10 mg 4.25 
20 mg 4.95 
40 mg 9.9 
Simvastatin 5 mg 2.12 
10 mg 2.41 
20 mg 3.42 
40 mg 6.83 
Laboratory test 
Fasting lipid profile profiles 132 
Outpatient clinic visit 
Specialist clinic per visit 700 
Hospital admission 
Accident & Emergency per visit 570 
General ward per day 3,300 
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